Abstract

Glioblastoma is the most common adult malignant primary brain tumor, and carries a dismal prognosis. After initial standard radiation therapy and chemotherapy with temozolomide, few standard chemotherapy options are available. In the last two decades, a growing understanding of molecular pathogenesis of glioblastoma has turned our focus toward targeted therapy. This review will discuss our current understanding of gliomagenesis and highlight the clinical attempts to manipulate these vital pathways, describing past and current studies, and future directions.

Original languageEnglish (US)
Pages (from-to)44-58
Number of pages15
JournalCurrent Cancer Therapy Reviews
Volume11
Issue number1
DOIs
StatePublished - Jul 1 2015

Keywords

  • Cell signaling
  • Glioblastoma
  • Gliomagenesis
  • Monoclonal antibodies
  • Targeted therapy
  • Tyrosine kinase inhibitors

ASJC Scopus subject areas

  • Molecular Medicine
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Targeted therapy for glioblastoma: Lessons learned and future directions'. Together they form a unique fingerprint.

Cite this